The Fly | FBIO

Broad and Diversified Pipeline: Fortress Biotech operates through a network of subsidiary companies, each focusing on distinct therapeutic areas and drug candidates, which diversifies risk and provides multiple opportunities for success across various development stages.

Strategic Subsidiary Model: The company's unique operational structure, where assets are developed within specialized subsidiary companies, enables focused resource allocation, attracts specialized talent, and creates potential for independent financing or spin-offs, enhancing shareholder value.

Experienced Management Team: Fortress Biotech benefits from a seasoned leadership team with extensive experience in pharmaceutical development, regulatory affairs, and commercialization, providing strategic direction and operational expertise crucial for advancing its diverse pipeline.

Clinical Trial Failure Risk: Fortress Biotech's drug candidates may fail to demonstrate efficacy or safety in clinical trials, leading to significant delays or abandonment of development efforts.

Regulatory Approval Uncertainty: Even if clinical trials are successful, there is no guarantee that the FDA or other regulatory agencies will grant marketing approval for the company's product candidates.

Capital Requirements and Dilution Risk: The company requires substantial additional capital to fund its research, development, and commercialization efforts, which may lead to further equity dilution for existing shareholders.

Clinical Trial Failure Risk: Fortress Biotech's drug candidates may fail to demonstrate efficacy or safety in clinical trials, leading to significant delays or abandonment of development efforts.